



California State Board of Pharmacy

1625 N. Market Blvd, Suite N219, Sacramento, CA 95834
Phone (916) 574-7900
Fax (916) 574-8618
www.pharmacy.ca.gov

BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY
DEPARTMENT OF CONSUMER AFFAIRS
GOVERNOR EDMUND G. BROWN JR.

NOTICE OF MEETING AND AGENDA
Communication and Public Education Committee
March 23, 2017

DATE/TIME: March 23, 2017, at 9:00 a.m.

PLACE: Department of Consumer Affairs
DCA Headquarters Building Two
1747 N. Market Blvd., Room 186
Sacramento, CA 95834

NOTE: Pharmacists and pharmacy technicians who attend in person may be awarded 2 hours of CE, in accordance with the Board's CE policy. Sign in and sign out on the day of the meeting will be required for the CE credit.

For verification of the meeting, call (916) 574-7935 or (916) 574-7900 or access the board's website at www.pharmacy.ca.gov. Meeting materials should be available on the board's website at www.pharmacy.ca.gov by March 17, 2017.

The meeting is open to the public and is accessible to the physically disabled. A person who needs a disability-related accommodation or modification in order to participate in the meeting may make a request by contacting Debbie Damoth at (916) 574-7935, by emailing debbie.damoth@dca.ca.gov or sending a written request to the Board of Pharmacy, 1625 N. Market Blvd., Suite N-219, Sacramento, CA 95834. Providing your request at least five business days before the meeting will help to ensure availability of the requested accommodation.

Discussion and action may be taken on any item on the agenda. The time and order of agenda items are subject to change at the discretion of the committee chairperson and may be taken out of order. In accordance with the Bagley-Keene Open Meeting Act, all meetings of the board are open to the public.

*NOTE: *Government Code Section 11125.7 provides the opportunity for the public to address each agenda item during discussion or consideration by the committee or prior to the committee taking any action on said item. Members of the public will be provided appropriate opportunities to comment on any issues before the committee, but the committee chairperson may, at his or her discretion, apportion available time among those who wish to speak. Individuals may appear before the committee to discuss items not on the agenda; however, the committee can neither discuss nor take official action on these items at the time of the same meeting (Government Code Sections 11125, 11125.7(a)).*

Agenda

Call to Order

9:00 a.m.

1. Call to Order and Establishment of Quorum
2. Public Comment for Items Not on the Agenda, Matters for Future Meetings*
**(Note: the committee may not discuss or take action on any matter raised during the public comment section that is not included on this agenda, except to decide to place the matter on the agenda of a future meeting. Government Code Sections 11125 & 11125.7(a))*
3. Discussion and Consideration of Recommendations for Patient-Focused Labeling Changes to California Law
 - a. Presentation and proposal from Chapman University School of Pharmacy
 - b. Next steps
4. Discussion and Consideration of Requirements Relating to Pharmacy Translations and Interpretations
 - a. Presentation by Office for Civil Rights of U.S. Department of Health and Human Services on Final Rule Implementing Section 1557 of the Affordable Care Act (ACA) Regarding Nondiscrimination in Health Programs and Activities
 - b. United States Access Board's Recommendations Related to Prescription Labels for Visually Impaired and Elderly Patients
 - c. NABP Request to Boards of Pharmacy Regarding Labeling Requirements for Emergency-Use Medications
 - d. Necessary Modifications to Pharmacy Law or Regulations relating to Translation and Interpretation Services, if any
5. Discussion and Consideration of Naloxone Matters
 - a. SB 833 (Committee on Budget and Fiscal Review, Health, Chapter 30, Statutes of 2016)
 - b. Federal Legislation: US S. 524 – Comprehensive Addiction and Recovery Act of 2016 (CARA) – Provisions Regarding Partial Fills for Schedule II
 - c. Availability of Naloxone at Pharmacies in Specific Communities, including Los Angeles County
 - d. Walgreen's Request to Use In-House Fact Sheet for Patients Receiving Naloxone
 - e. Outreach Efforts to Licensees Regarding Naloxone Protocol and Training/CE Requirements
6. Update and Discussion on Development of FAQs for SB 493 Items
7. Update and Discussion of a Board-Developed Public Service Billboard Message and Related Communication Materials

8. Update and Discussion on Development and Implementation of Communication Plan for Reaching Consumers and Licensees
9. Discussion of Efforts by Drug Manufacturers to Stop Illegal Sales of Non-FDA Approved Products
10. Update on the Status and Implementation of the Approved Regulation Title 16, CCR section 1707.5, Regarding Patient-Centered Labels for Prescription Drug Containers
11. Update on *The Script* Newsletter
12. Update on Media Activity
13. Update on Public Outreach Activities Conducted by the Board
14. Review and Discussion of News or Journal Articles
15. Future Meeting Dates for 2017
 - a. June 28, 2017
 - b. September 20, 2017
 - c. December 13, 2017

Adjournment

2:00 p.m. or upon conclusion of business